Purpose: To audit the use of GIK in terms of safety, haemodynamic effects, and impact on catecholamine dosage. Materials and methods: A retrospective, descriptive, evaluative audit of GIK use within the adult ICU of a London teaching hospital was conducted. Rescue therapy of GIK (up to 1.0 Units insulin/kg/h) was administered to improve cardiac function. Outcomes were ICU survival, change in cardiac index (CI) and blood lactate levels, events of hypoglycaemia, hyperglycaemia, hypokalaemia and hyperkalaemia, and discontinuation time of catecholamine inotropes. Results: Of 85 patients treated with GIK, 13 (15.3%) survived their ICU stay and 9 (10.5%) were discharged home. In patients surviving until 72 h, a trend of improved CI and lactate levels was seen, often with reductions in catecholamine dosing. Inotropes were discontinued in 35 (54%) patients. Severe hypoglycaemia (b2 mmol/l), hyperglycaemia (N20 mmol/l), hypokalaemia (b 2.5 mmol/l) and hyperkalaemia (N7 mmol/l) during GIK affected 1, 6, 8 and 1 patients, respectively. These abnormalities were quickly identified. No measurable harm was noted. Conclusions: High-dose GIK can be safely used in critically ill patients, though blood glucose and potassium levels must be monitored frequently. GIK was associated with improved CI and blood lactate levels. Impact on survival requires prospective evaluation.
Introduction
Heart failure is a severe disease with a high morbidity and mortality. In 2012/2013, 0.74% of all inpatient episodes in National Health Service hospitals in the United Kingdom were caused by heart failure [1] . In that year, 9.4% of the heart failure patients in England died in-hospital, and 24.6% died within a 1 year follow-up period [2] . Critically ill patients with heart failure and cardiogenic shock are typically treated with catecholamine inotropes as these increase myocardial contractility and myocardial perfusion, and improve cardiac output. If vascular tone is low, drugs with a predominant vasoconstrictor action (norepinephrine, vasopressin, terlipressin) are generally given, whereas inotropes such as epinephrine and dobutamine are commonly used to enhance cardiac output [3] .
Use of catecholamines can however be harmful in multiple ways including immunomodulation, increased bacterial growth and virulence, decreased metabolic efficiency, myocardial damage, increased cardiac work, and pro-thrombotic and pro-arrhythmogenic tendencies [4] . Indeed, even adjusting for severity and other factors, these agents are associated with a significantly increased risk of greater morbidity, mortality and rehospitalisation [5] [6] [7] . Other options for treating low cardiac output states include phosphodiesterase inhibitors such as enoximone or calcium sensitizers such as levosimendan. Both agents can sometimes cause excessive vasodilation [8] , while phosphodiesterase inhibitors have been associated with worse outcomes [9, 10] .
Because of the putative beneficial effects of glucose-insulin-potassium (GIK) infusions in patients with low cardiac output states [11] , we started to use low dose GIK (with 0.075 Units insulin/kg/h) within our intensive care unit 8 years ago [12] . This showed promising results in terms of improving arterial lactate levels and augmenting cardiac output. More recently, case series, predominantly in patients being treated for overdoses with beta-adrenergic blockers and/or calcium channel blockers, have used much higher doses of insulin (usually 0.5-1 Units/ kg/h but, sometimes, up to 3 Units/kg/h or even higher) to augment low output states [13, 14] . Haemodynamic benefits with an excellent safety profile were reported. These positive data encouraged us to move to a high-dose GIK regimen (0.25-1.0 Units insulin/kg/h) from 2012 onwards as a treatment strategy for patients with low cardiac output who were not responding effectively to high-dose catecholamines. Clearly, the risk of hypo-or hyperglycaemia, as well as hypo-and hyperkalaemia would likely be increased with the use of these high doses. A protocol was thus developed to manage the high-dose GIK regimen safely with a staff education campaign preceding. As this strategy has become adopted into our routine clinical practice, we decided to audit the use of high-dose GIK, with a focus on safety and haemodynamic effects.
Material and methods

Setting and study population
This retrospective, descriptive evaluative audit of usual practice was carried out in the mixed adult 35-bed ICU of University College London Hospital, a tertiary care teaching hospital in the United Kingdom. Our protocol aimed to treat patients with myocardial depression who had not responded to conventional catecholamine therapy, with high-dose GIK. All patients treated with GIK with an ICU admission between December 2012 and March 2015 were included, there were no exclusion criteria.
To implement high-dose GIK, staff were asked to follow a protocol aiming to increase cardiac index (CI) ( Table 1 ). This protocol was adapted from Marini et al. who applied a GIK strategy for treating calcium channel and bèta blocker overdoses (Dr. John Marini, personal communication). The protocol requires patients to be treated with catecholamines and have serum glucose levels N 7 mmol/l and potassium levels N4 mmol/l prior to commencing the GIK infusion. After giving glucose and insulin boluses, separate infusions were started at a rate of 0.25 Units insulin/kg/h, 10 ml/h 50% glucose solution and 10 mmol/h potassium. For patients in whom no significant improvement was seen, the insulin dose could be up-titrated after 1 h to 0.5 Units/kg/h and, if needed, to 1.0 Units/kg/h. The 50% glucose infusion rate could be uptitrated to 15 ml/h and 20 ml/h, respectively. Glucose and potassium levels were required to be monitored hourly and the infusion rates adjusted to achieve normal blood glucose (4-10 mmol/l) and potassium levels (3.8-5.0 mmol/l). Once stabilised, the frequency of monitoring could be reduced. When stopping the GIK infusion, insulin should be reduced to half its previous infusion rate at 8-24 hourly intervals. After GIK discontinuation, glucose should be continued for 12-24 h.
Patient outcomes were manually collected from the Philips IntelliVue Clinical Information Portfolio (ICIP) Electronic Health Record and MUSE Cardiology Information System. Blood gas measurements were carried out with a Roche Cobas B221 blood gas analyser. Cardiac output was monitored using oesophageal Doppler ultrasonography (Deltex Medical, Chichester, Sussex, UK); CI was calculated subsequently by dividing cardiac output by body surface area. We considered 2.6-4.2 l/min/m 2 as a normal range for CI. The underlying reason to start GIK was recorded. Sepsis was defined using standard definitions [15] . A Sequential Organ Failure Assesment (SOFA) score was calculated for each patient [16] . As the central nervous system score could not be defined for sedated patients, they were scored 0 (normal) unless evidence of prior abnormality existed. Patient consent and Ethical Committee review is not required in the UK for research limited to secondary use of information previously collected in the course of normal care (without an intention to use it for research at the time of collection), provided that the patients or service users are not identifiable to the research team in carrying out the research [17] . • Monitor BG every 10 min and titrate glucose 50% infusion (G50%) to achieve target of 4-10 mmol/l. If BGs are stable, monitor the BG every hour
• Monitor blood potassium levels every hour
Step 1
Step 2
Step 3
Step 4
Step 5 
Outcomes
The following measures were collected for each individual patient, investigated and analysed interindividually:
1) ICU and in-hospital survival.
2) Daily dose and duration of glucose, insulin and potassium.
3) CI at time points − 6, 0, 6, 12, 24, 48 and 72 h, after starting the GIK infusion where 0 h represents the start time of GIK. 4) Arterial lactate levels at time points −12, 0, 12, 24 and 48 h after starting the GIK infusion where 0 h is the start time of GIK. 5) Incidence, duration and maximum/minimum level of hypoglycaemia (b2.2 mmol/l), hyperglycaemia (N10 mmol/l), hypokalaemia (b 3 mmol/l) and hyperkalaemia (N5.4 mmol/l) events before and during GIK. Hyperglycaemic severity was divided in N 10, N15 and N20 mmol/l subsets and hyperkalaemic severity in N 5.5, N 6 and N 7 mmol/l subsets. Asystolic events related to hyperkalaemia were also reported.
6) Time on vasoactive drugs before and during GIK and the total time on vasoactive drugs.
7) Discontinuation and duration of the use of inotropes and norepinephrine.
8) Use of enoximone, levosimendan, terlipressin and vasopressin during GIK.
Statistics
Data analysis was performed using SPSS version 20.0 (IBM). A Shapiro Wilk test with a visual inspection of the histogram, Q-Q plots and boxplots showed that obtained data were not normally distributed, hence nonparametric tests were used. Unless otherwise stated all values are given as median (interquartile range). Diffences between ICU survivors and non-survivors were analysed using Wilcoxon rank sum test (median values) and Fisher's exact test (proportions). Spearman's rho was used to analyse correlations between hyperglycaemic events and mortality, but also between the daily insulin dose and potassium and glucose doses, and between the daily insulin dose and hypoglyceamic and hypokalaemic events. In view of the high early mortality rate in this very sick group of patients, outcome statistics were not performed.
Results
Demographics
During the audit period, 85 patients received GIK commencing a median (IQR) 1 (1-3) days after ICU admission. Patient demographics are presented in Table 2 . Seventy (82.4%) patients were primarily admitted to ICU for a medical condition and 15 (17.6%) post-operatively. Overall, baseline cardiac index was low 2.5 (2.0-3.2) l/min/m 2 , while SOFA [11 (9-13) ] and APACHE II [25 (19-32) ] scores were high. Sepsis was present in 83.5%, while 11.8% of the patients had cardiogenic shock.
Thirteen patients (15.3%) survived their ICU stay, and nine were discharged from hospital. ICU survivors stayed for 59 (20-90) days in hospital including 19 (9-39) days in ICU. The ICU non-survivor group had more patients with haematological malignancies than the survivor group (66.7% vs. 14.4%; p b 0.05), and more patients receiving mechanical ventilation (85% vs. 62%; p b 0.05).
Forty-four of the 72 ICU non-survivors (61%) died while the GIK infusion was ongoing, after a median of 23 (10-62) h. Of the 28 patients who died in ICU after discontinuation of GIK, six died from non-cardiac causes more than seven days later, despite improvement in their myocardial function. Table 3 shows doses of GIK administered. Forty-nine of the 85 patients remained at the lower dose of 0.25 Units insulin/kg/h though one patient was commenced at a higher dose (0.5 Units insulin/kg/h). Survivors needed more glucose than non-survivors [16 (10-18) vs. 5 (11) (12) (13) (14) (15) (16) (17) (18) (19) g/h; p b 0.01] to maintain normoglycaemia when administered a dose of 0.25 Units insulin/kg/h, whereas no differences were seen when given higher doses of insulin. Potassium doses were similar at the different doses of insulin. The daily dose of insulin was 540 (396-744) Units per patient. Patients received a daily glucose dose of 439 (313-621) g, which comprised GIK, other medications and enteral/parenteral nutrition. The daily potassium dose was 111 (56-154) mmol. Even though potassium and glucose requirements increased in all patients with insulin dosing, only a weak correlation was seen between daily glucose and insulin dose (ρ = 0.47, p b 0.01) and no significant correlation was seen between daily potassium supplementation and the insulin dose (ρ = 0.10, p = 0.36).
Doses of GIK
Lactate levels and cardiac index
Lactate levels in ICU survivors were 3.3 (1.4-10.9) at the start of treatment and 2.2 (1.4-2.5) mmol/l at 72 h. In decedents who survived N72 h after GIK was started, lactate levels fell from 7.1 (4.3-10.7) to 4.4 (3.4-5.5) mmol/l at 72 h. SOFA score on GIK day 1 11 (9-13) 9 (8-
Reason to start GIK: -Heart failure/cardiogenic shock 10 (11.8%) 1 (7.6%) 
Hypoglycaemic events
Three patients had three hypoglycaemic events each during GIK, whereas no patient experienced a hypoglycaemic event between ICU admission and commencing GIK. The lowest glucose level recorded was 1.9 mmol/l and this was promptly normalized. No association was found between hypoglycaemic events and the dose of insulin (ρ = 0.70, p = 1.00).
Hyperglycaemic events
Between ICU admission and before commencing GIK, 57 (67.1%) patients had 1 (1-2) hyperglycaemic events with a highest median blood glucose level of 13.9 (11.5-15.6) mmol/l] for a duration of 5 (2-7) h. A total of 101 (80%) events exceeded a blood glucose level of 10 mmol/l, 19 (15%) exceeded 15 mmol/l and 6 (5%) exceeded 20 mmol/l. Twenty-one hyperglycaemic events occurred before starting GIK and ending during GIK; correction was achieved within 2 (1-5) h. No association was found between hyperglycaemic events and mortality (ρ = 0.13, p = 1.00).
Fifty-five (64.7%) patients had 2 (1-3) hyperglycaemic events during GIK administration with a highest blood glucose level of 13.3 (11.6-17.7) mmol/l. Of these events, 89 (78%) exceeded a blood glucose of 10 mmol/l, 17 (15%) exceeded 15 mmol/l and 8 (7%) exceeded 20 mmol/l. The duration of these events was 3 (2-4) h. Three events occurred while the dose of GIK was decreasing with the intention of stopping GIK, and seven while increasing the dose of glucose.
Hypokalaemic events
One patient had two hypokalaemic events (lowest level 2.7 mmol/l) before GIK was initiated. Each event was corrected within 1 h. Another patient had a hypokalaemic event during GIK with a minimum potassium level of 1.2 mmol/l. This was corrected within 2 h and was not associated with any adverse effect. No association was found between insulin dose and the hypokalaemic events (ρ = 0.05, p = 0.64).
Hyperkalaemic events
Thirty-nine (45.9%) patients had 1 (1-2) hyperkalaemic event between ICU admission and commencing GIK. The highest potassium level was 6 (5.6-6.4) mmol/l. Of these events, 25 (64.1%) had a potassium level between 5.5 and 6.0 mmol/l, 13 (33.3%) between 6.1 and 7.0 mmol/l and 1 (2.6%) exceeded 7 mmol/l. These events lasted a median of 4 (2-6) h. There were 17 hyperkalaemic events starting before GIK and ending during GIK, needing 2 (2-5) h to achieve normokalaemia.
Forty-one (48.2%) patients had 1 (1-2) hyperkalaemic events during GIK with a highest potassium level of 6.0 (5.7-6.7) mmol/l. Of these events, 47 (72.3%) were between 5.5 and 6.0 mmol/l, 12 (18.5%) between 6.1 and 7.0 mmol/l and 6 (9.2%) exceeded 7.0 mmol/l. The hyperkalaemic events had a duration of 4 (2-7) h. Levels were corrected by reducing the amount of potassium infused. Ten percent of patients received intravenous calcium. No asystolic events were seen.
Inotropes and vasopressors
The use of inotropes and vasopressors is described in Table 4 . Overall, vasoactive drugs were started 12 (2−30) h before commencing GIK. Epinephrine was used in 68% of patients, 21 (25%) patients were given dobutamine and 7 (8%) patients received levosimendan, some in combination. One (1%) patient was given enoximone. Patients were treated with vasoactive drugs for 79 (36-159) h, of which 21 (6-54) hours occurred during GIK administration. Inotropes were discontinued in all survivors and in 26 (46%) of the non-survivors. Twenty (24%) patients were not treated with epinephrine or dobutamine. Norepinephrine was used in 54 (64%) patients before GIK started. During the GIK infusion, norepinephrine was co-administered with inotropes in 54 (64%) patients while 16 (19%) patients received noradrenaline without inotropes. Terlipressin was used in 18 (21%) and vasopressin in 2 (2%) patients.
Discussion
This evaluation offers insight into the safety and haemodynamic effects of high-dose GIK infusion to augment cardiac performance in patients with severe critical illness requiring high-dose catecholamine infusions. We report overall improvement in blood lactate levels and CI over the first 72 h. Catecholamine inotropes could be discontinued in more than half of the patients while GIK was being administered. While a minority experienced episodes of severe hypoglycaemia, hyperglycaemia, hypokalaemia and hyperkalaemia, these were quickly identified and corrected, with no obvious harm coming to the patient. Clearly, close monitoring of blood glucose and potassium is mandatory during administration of high-dose GIK, particularly around dose transition.
Due to the potential harm induced by exogenous catecholamine therapy [5] [6] [7] , a less harmful strategy such as GIK may be beneficial. The hyperadrenergic state of heart failure causes plasma free fatty acid (FFA) levels to rise [18] [19] [20] . This increases insulin resistance and decreases cellular use of glucose. As a consequence, energy, in the form of adenosine triphosphate (ATP), needs to be liberated from fat instead of glucose and this requires approximately 11-12% more oxygen consumption [21] . As coronary sinus oxygen tensions are normally low, blood flowing through narrowed coronary vessels in ischaemic heart disease has to increase further to deliver additional oxygen, and this may not be achievable. A compensatory increase in anaerobic glycolysis occurs, however this is a less efficient producer of ATP compared to aerobic respiration (oxidative phosphorylation). A decrease in oxidative phosphorylation caused by inhibition of the fatty acid transporter, acylpalmitoyltransferase-1 (APT-1), may also result in less oxidation of FFA, thereby increasing plasma levels still further [22] . High levels of FFA have pro-inflammatory and pro-oxidant actions and reduce mitochondrial efficiency [23, 24] .
Such metabolic effects may explain the postulated clinical benefit of GIK in the treatment of heart failure. Firstly, insulin promotes oxidative phosphorylation [25] . Second, insulin inhibits lipolysis, which results in a decrease of circulating FFA and allows the heart to use glucose for ATP production. As glucose is the preferred energy substrate for stressed myocardial cells [19, 20] , this should be beneficial. Third, insulin induces dose-dependent vasodilation via the L-arginine-NO-pathway; this is hypothesised to improve coronary blood flow and thus contractility of the dysfunctional left ventricle [26, 27] . As a consequence, there is an increase of intracellular glucose transport into cardiac muscle. It remains unclear whether the effect of GIK relies on a decrease of FFA and/or an increase in glucose utilization [28] . As insulin decreases blood glucose and potassium levels, potassium and glucose are integral constituents of the GIK regimen to maintain normoglycaemia and normokalaemia.
GIK has been studied in acute myocardial infarction [11, 28, 29] and cardiac surgery [30] [31] [32] , albeit with variable results and thus no overall benefit [33] . Possible reasons include use of different doses of insulin, failure to maintain normoglycaemia, and introduction after thrombolysis where high blood sugar levels may have enhanced the degree of reperfusion injury. A study in 15 septic shock patients showed short-term haemodynamic improvement following a 20-minute GIK infusion [34] , while a pilot study in patients with heart failure showed beneficial effects of GIK on systolic function [35] .
As high-dose GIK (0.25-1.0 Units/kg/h, but sometimes much higher) now has a recommended role in beta-blocker and/or calcium channel blocker overdose [13, 14] , we predicted a better response in our patient population with higher doses of insulin than our former practice using 0.075 Units/kg/h. Our insulin dose regimen was also much higher than in studies using GIK after myocardial infarction and surgery [33] .
The inconsistencies of clinical practice were exposed by our audit. The insulin dose remained at 0.25 Units/kg/h in the majority of patients, rather than being titrated upwards as per our guideline for patients in whom a clinically relevant reduction in catecholamines was not seen within the first few hours. Whether higher doses would have offered better results and/or increased the incidence of adverse events is unknown. As we found, higher glucose dosing would be required as insulin causes a net intracellular shift [36] . Whether potassium supplementation would also need to be increased requires further study, as we did not find any correlation between insulin dose and degree of potassium supplementation. A further breach of our ICU protocol was the use of GIK in some patients not receiving inotropes for a low cardiac output state and, in a few instances, not receiving catecholamines. This emphasizes the need for continuing education about its likely biological effects and clinical indications, and closer policing, which have since been instituted. While mild-to-moderate hyperglycaemic and hyperkalaemic events were common during GIK administration, the incidence was identical to that seen in patients before commencement of the GIK infusion. As described above, severe events were uncommon and promptly corrected.
Regardless of any improvement in haemodynamic and tissue metabolic status, mortality was still very high in this subset of shocked patients. Their baseline APACHE II and SOFA scores and the high incidence of underlying immunosuppression, especially related to haematological malignancy, underlines their poor prognosis.
A limitation of the study is its retrospective nature. Some measurements were missing from our Electronic Health Record at particular time points. Furthermore, there is no control group as would be required in a prospective study. However, we do feel there are sufficient grounds in terms of benefits and relatively low risks to proceed to a randomised controlled trial of high-dose GIK in critically ill septic patients with myocardial depression, in whom the literature is very sparse. It is nonetheless important to carefully characterize the group(s) of patients who would most likely benefit.
Conclusions
High-dose glucose-potassium-insulin infusions can be safely used in critically ill patients, though blood glucose and potassium levels must be monitored frequently. GIK was associated with improved cardiac output and blood lactate levels. The impact of this therapeutic strategy on survival requires prospective evaluation. 
